Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

Suspensión aplicable por vía oral de un principio activo farmacéuticamente del tipo de Fármacos No-Esteroides Anti-Inflamatorios (FNEAI) seleccionado a partir del ácido acetilsalicílico o un FNEAI de las siguientes categorías a) un derivado de ácido propiónico seleccionado a partir de Ibuprofen Naproxen Flurbiprofen Fenoprofen Fenbufen Ketoprofen Indoprofen Pirprofen Carprofen Oxaprozin Pranoprofen Miroprofen Tioxaprofen Suprofen Alminoprofen ácido tiaprofénico y Fluprofeno a las sale...

E' descritto un procedimento per la preparazione degli enantiomeri otticamente puri del Suprofen di formula (I) (FORMULA I) che comprende l'esterificazione dell'acido racemo con un alcol alifatico inferiore in presenza di lipasi.

PURPOSE: To provide a pharmaceutical composition useful for the treatment of pain and tussis which comprise a tramadol substance and non-steroidal anti-inflammatory drug and shows synergistic analgesic effects with a small amount of dosage wand with less side-effects such as abuse liability tolerance constipation respiratory depression.CONSTITUTION: The pharmaceutical composition is composed of tramadol i.e. (1R2R or 1S2S)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol its N-oxide der...

Method using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in cell function when bound to a specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be administered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of a cornea ...

Disclosed are esters and amides of (+) suprofen, substantially free of the corresponding enantiomorp, (-) suprofen, having enhanced delivery characteristics on topical administration to the eye;also disclosed are pharmaceutical compositions comprising such (+) suprofen derivatives and methods of using them when indicated to achieve an anti-inflammatory effect on topical delivery to the eye.